Our findings demonstrate that de novo pyrimidine biosynthesis represents a collateral metabolic vulnerability induced by NF2 deficiency in PM, reinforcing the notion that specific oncogenic mutations can rewire the canonical pyrimidine metabolism pathway and may thus be targeted therapeutically. Here, NF2 is linked to hyperinsulinemic hypoglycemia, familial, 4.